Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study
- PMID: 26421817
- DOI: 10.1016/j.ejca.2015.07.043
Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study
Abstract
Background: Head and neck (H&N) cancers are a heterogeneous group of malignancies, affecting various sites, with different prognoses. The aims of this study are to analyse survival for patients with H&N cancers in relation to tumour location, to assess the change in survival between European countries, and to investigate whether survival improved over time.
Methods: We analysed about 250,000 H&N cancer cases from 86 cancer registries (CRs). Relative survival (RS) was estimated by sex, age, country and stage. We described survival time trends over 1999-2007, using the period approach. Model based survival estimates of relative excess risks (RERs) of death were also provided by country, after adjusting for sex, age and sub-site.
Results: Five-year RS was the poorest for hypopharynx (25%) and the highest for larynx (59%). Outcome was significantly better in female than in male patients. In Europe, age-standardised 5-year survival remained stable from 1999-2001 to 2005-2007 for laryngeal cancer, while it increased for all the other H&N cancers. Five-year age-standardised RS was low in Eastern countries, 47% for larynx and 28% for all the other H&N cancers combined, and high in Ireland and the United Kingdom (UK), and Northern Europe (62% and 46%). Adjustment for sub-site narrowed the difference between countries. Fifty-four percent of patients was diagnosed at advanced stage (regional or metastatic). Five-year RS for localised cases ranged between 42% (hypopharynx) and 74% (larynx).
Conclusions: This study shows survival progresses during the study period. However, slightly more than half of patients were diagnosed with regional or metastatic disease at diagnosis. Early diagnosis and timely start of treatment are crucial to reduce the European gap to further improve H&N cancers outcome.
Keywords: Europe; Head and neck cancers; Hypopharynx; Larynx; Nasopharynx; Oral cavity; Oropharynx; Population-based study; Survival; Tongue.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Similar articles
-
Prognoses for head and neck cancers in Europe diagnosed in 1995-1999: a population-based study.Ann Oncol. 2011 Jan;22(1):165-174. doi: 10.1093/annonc/mdq306. Epub 2010 Jun 29. Ann Oncol. 2011. PMID: 20587510
-
Italian cancer figures--Report 2015: The burden of rare cancers in Italy.Epidemiol Prev. 2016 Jan-Feb;40(1 Suppl 2):1-120. doi: 10.19191/EP16.1S2.P001.035. Epidemiol Prev. 2016. PMID: 26951748
-
Survival for oesophageal, stomach and small intestine cancers in Europe 1999-2007: Results from EUROCARE-5.Eur J Cancer. 2015 Oct;51(15):2144-2157. doi: 10.1016/j.ejca.2015.07.026. Epub 2015 Sep 26. Eur J Cancer. 2015. PMID: 26421818 Free PMC article.
-
Descriptive epidemiology of the head and neck cancers in old patients.Front Oncol. 2023 May 24;13:1102236. doi: 10.3389/fonc.2023.1102236. eCollection 2023. Front Oncol. 2023. PMID: 37293589 Free PMC article. Review.
-
Cancer Patients' Survival: Standard Calculation Methods And Some Considerations Regarding Their Interpretation: POPULACIJSKO PREŽIVETJE BOLNIKOV Z RAKOM: UPORABA RAZLIČNIH PRISTOPOV IN PROBLEMI INTERPRETACIJE REZULTATOV.Zdr Varst. 2016 Feb 11;55(2):134-41. doi: 10.1515/sjph-2016-0012. eCollection 2016 Jun 1. Zdr Varst. 2016. PMID: 27284384 Free PMC article. Review.
Cited by
-
New Tumor Budding Evaluation in Head and Neck Squamous Cell Carcinomas.Cancers (Basel). 2024 Jan 30;16(3):587. doi: 10.3390/cancers16030587. Cancers (Basel). 2024. PMID: 38339338 Free PMC article.
-
Validation of a deep-learning segmentation model for adult and pediatric head and neck radiotherapy in different patient positions.Phys Imaging Radiat Oncol. 2023 Dec 27;29:100527. doi: 10.1016/j.phro.2023.100527. eCollection 2024 Jan. Phys Imaging Radiat Oncol. 2023. PMID: 38222671 Free PMC article.
-
Matrix Metalloproteinases and Their Inhibitors as Potential Prognostic Biomarkers in Head and Neck Cancer after Radiotherapy.Int J Mol Sci. 2023 Dec 30;25(1):527. doi: 10.3390/ijms25010527. Int J Mol Sci. 2023. PMID: 38203696 Free PMC article. Review.
-
Survival in oral and pharyngeal cancers is catching up with laryngeal cancer in the NORDIC countries through a half century.Cancer Med. 2024 Jan 2;13(1):e6867. doi: 10.1002/cam4.6867. Online ahead of print. Cancer Med. 2024. PMID: 38164108 Free PMC article.
-
Inhibition of EIF2α Dephosphorylation Decreases Cell Viability and Synergizes with Standard-of-Care Chemotherapeutics in Head and Neck Squamous Cell Carcinoma.Cancers (Basel). 2023 Nov 9;15(22):5350. doi: 10.3390/cancers15225350. Cancers (Basel). 2023. PMID: 38001610 Free PMC article.
LinkOut - more resources
Full Text Sources
Miscellaneous
